Acknowledgements were made to Beverley Jones, Susan Knight, and Deborah Symmons (Macclesfield District General Hospital), in this publication.
by Wan-Fai Ng
Musculoskeletal Research Group
Institute of Cellular Medicine
Introduction: Primary Sjögren’s syndrome (pSS) is a chronic multisystem disease affecting 0.3%–0.5% of the adult population.1, 2 Women are nine times more likely to be affected than men.1–4 The disease is characterized by oral and ocular dryness, fatigue, and musculoskeletal pain. PSS can affect other organ systems including the skin, nervous system, lungs, and kidneys.3, 4 Patients with pSS have a greater than 40-fold increased risk of developing B-cell mucosa-associated lymphoid tissue (MALT) lymphoma.4, 5 Patients with PSS have poor health-related quality of life and a significant proportion of PSS patients are unable to work due to their condition.2, 6–17 Both direct and indirect health care costs are higher in PSS than in the general population.17, 18 PSS is not, therefore a benign condition, but has a significant health and economic burden to patients and society.